![Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors](/docs/US/2022-10-04/US11459334B2/abs.jpg.600x600.jpg)
- 专利标题： Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
-
申请号： US17044697申请日： 2019-04-15
-
公开(公告)号： US11459334B2公开(公告)日： 2022-10-04
- 发明人: Yihan Wang , Huanyin Li
- 申请人： SHENZHEN TARGETRX, INC.
- 申请人地址： CN Guangdong
- 专利权人： SHENZHEN TARGETRX, INC.
- 当前专利权人： SHENZHEN TARGETRX, INC.
- 当前专利权人地址： CN Guangdong
- 代理机构： Kilpatrick Townsend & Stockton LLP
- 优先权： CN201810339098.1 20180416
- 国际申请： PCT/CN2019/082618 WO 20190415
- 国际公布： WO2019/201194 WO 20191024
- 主分类号： A61K31/53
- IPC分类号： A61K31/53 ; C07D487/04
![Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors](/abs-image/US/2022/10/04/US11459334B2/abs.jpg.150x150.jpg)
摘要：
Provided in the present invention are a substituted pyrrolotriazine compound, a pharmaceutical composition thereof and a use thereof, the pyrrolotriazine compound being a compound represented by formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate or solvent compound, crystalline form, stereoisomer or isotope variant thereof. The compound and composition of the present invention may be used in the treatment of conditions associated with KIT and/or PDGFRα.
公开/授权文献
信息查询
